Kornimate/medical-research-clean huggingface dataset:
study of adhd children's sensitivity to memory error production

Conditions: ADHD

Summary: the purpose of the study is to test whether children with attention deficit/hyperactivity disorder (adhd) are more susceptible to false memory production using a drm paradigm. the number of "critical decoy production" errors will be analyzed and compared to the calibration of the test.

during a neuropsychological assessment, as part of the clinical routine, children with a diagnosis of adhd, without neurological etiology, aged 8 to 10 years will be offered an additional task. this task, a drm adapted to the child, consists of learning several lists of words. each list exposes words belonging to the same lexical field, to a concept not explicitly mentioned in the list, called critical lure. immediately after the presentation of a list, the child is asked to recall as many words as possible. recall of the critical lure gives an indication of the production of false memories. the number of critical lures produced by these children will be compared to the calibration of the test, currently being published. the investigator will also verify if the production of critical lures can be correlated with other variables such as performance on intellectual, executive and attentional tasks, proposed during the clinical routine assessment. the investigator hypothesize that adhd children will recall more critical lures than the norm, and fewer correct responses than the norm. the data collected is taken from the child's psychological file. the only personal information used, beyond test performance, is the child's gender and age. the procedure is anonymous.

Eligibility criteria:
inclusion criteria: * age between 96 and 131 months * child referred by a doctor for a neuropsychological assessment * child with adhd diagnosis * sufficient command of the french language * non-opposition of the child and his/her parents exclusion criteria: * severe psychiatric comorbidity: major depressive episode, bipolar disorder, generalized anxiety disorder, autism spectrum disorder * major neurological history: severe head trauma, stroke, severe epilepsy, brain tumor * repeating a class during school * presence of an intellectual disability * use of methylphenidate treatment less than 48 hours before the experiment * completion of an intellectual assessment using the wechsler intelligence scale for children (wisc-v) dated less than one year before the meeting
presence 2: predicting sedentary entertainment choices and effects

Conditions: Obesity; Physical Activity

Summary: the purpose of this study is to determine whether playing motion-controlled video games produces low caloric intake and higher caloric expenditure than watching tv or playing traditional video games.

the purpose of this study is to investigate differences in behaviors and emotions during tv watching and video game playing. participants will be randomized to either watch tv, play traditional button-based video games, or play motion-based video games for one hour while palatable snack foods and sugar-sweetened beverages are provided within easy reaching distance. both energy intake as well as energy expenditure during a one-hour period will be measured. all three conditions will be optimized to resemble typical in-home conditions as much as possible. an additional goal of this study is to provide insight into the possible pathways by which tv and video games differentially affect intake and expenditure. distraction from the real world (also called presence or engagement) will be analyzed to determine if a) these variables differ across groups and b) if these variables explain differences in energy intake and/or expenditure. the tv group will watch tv shows using netflix streaming service, which will allow them to choose from a variety of popular shows without viewing commercials. as the investigators are primarily interested in satiety and hand occupation effects, the lack of commercials will allow us to eliminate food advertisements as a causal factor. finally, the third major goal of the study is to investigate how young adults choose screen-based media. in the two video game arms, participants will be allowed to choose to play any of 10 provided games, and in the tv group, participants will be able to choose from hundreds of options. choices of game/program, time spent on each game/program, and psychological reactions to each game will be measured and analyzed.

Eligibility criteria:
inclusion criteria: * between the ages of 18 and 35 years old exclusion criteria: * not at least a novice video game played (defined as having played games once or twice within the last year) * has pre-existing medical condition that precludes physical activity * is unable to find transportation to the study center * does not agree to be videotaped during the experiment * does not agree or is unable to fast for two hours prior to the experiment * is pregnant or nursing * weighs more than 300 pounds (required by one of the game controllers)

Keywords: energy intake video games television physical activity obesity
palonosetron for the treatment of nausea and vomiting in terminally ill patients

Conditions: Nausea; Vomiting; Terminally Ill

Summary: the primary objective of this study is to determine the complete response (no vomiting and no need for other medications to treat nausea) in terminally ill patients suffering from nausea and/or vomiting, who are treated with palonosetron. another objective is to determine the partial response (relief of nausea and vomiting to the extent that the patient wishes to continue treatment with palonosetron) after being treated with palonosetron. palonosetron is currently approved by the fda to prevent nausea and vomiting associated with chemotherapy. the investigators are testing this medication to see if it can help to relieve nausea and vomiting not associated with chemotherapy.


Eligibility criteria:
inclusion criteria: 1. patient must be at least 18 years old. 2. patient must have a terminal diagnosis, with estimated survival of 6 months or less. 3. patients must have nausea and/or vomiting, not relieved with 1 or more anti-nausea medications. if the patient is treated with an anti-nausea medication, a minimum of 2 hours should pass to ensure that the medication is given a chance to be effective. if there is no relief after 2 hours, then the patient may be treated with palonosetron. 4. patient's medications must be reviewed. any medications possibly causing nausea should be stopped if possible. for example, if an opiate is suspected of causing nausea, another opiate should be substituted. however, if this is not effective, or if a medication change cannot be made, then the patient would be eligible for this study. 5. patient must be able to understand and sign informed consent 6. patients who have a bowel obstruction that will not be relieved by surgery may be enrolled. this includes patients whose obstruction is technically unresectable, or who are medically too ill to endure a surgery, or who refuse surgical intervention for any reason exclusion criteria: 1. patient has received chemotherapy in the past 28 days. 2. assessment of possible causes of the nausea and vomiting should be done and recorded. if a reversible cause of the nausea is identified, that cause should be treated if possible. if the treatment relieves the nausea, then the patient is excluded from this study. possible reversible causes of nausea and vomiting that should be excluded are: * other medical conditions such as benign positional vertigo, etc.
e-cigarettes and blood vessel function

Conditions: Nicotine Dependence

Summary: randomized controlled trial of electronic cigarettes with nicotine, without nicotine, and sham control, on endothelial function and markers of oxidative stress.

participants will use an electronic cigarette on 3 occasions: 1) with nicotine, 2) without nicotine, 3) sham control, and undergo a measure of endothelial function called brachial artery flow mediated dilatation (fmd). additionally, oxidative stress will be measured pre and post exposure.

Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * cardiac disease * respiratory disease * diabetes mellitus

Keywords: nicotine endothelial function oxidative stress
quantifying oxygen utilization of tumors using oxygen-enhanced molecular mri

Conditions: Malignant Brain Neoplasm

Summary: this trial looks to study the safety and feasibility of using oxygen-enhanced molecular mri to understand how cancer cells use oxygen differently than normal cells. cancer cells tend to utilize (or not utilize) oxygen differently than normal cells. by using the oxygen-enhanced molecular mri, researchers will be able to create spatial "maps" depicting areas of abnormal oxygen utilization unique to cancer. this type of information may be useful for diagnosing new cancers, understanding various "subtypes" of cancer that might utilize oxygen differently, or this information may be useful for evaluating new drugs that impact cancer metabolism.

primary objectives: i. determine the safety, feasibility, and sensitivity of oxygen-enhanced molecular magnetic resonance imaging (mri) in healthy volunteers. ii. measure oxygen-enhanced molecular mri characteristics in human brain tumors. outline: participants undergo arterial spin labeling (asl) mri scan and amine chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging using amine proton cest echo spin-and-gradient echo (sage) epi (cest-sage-epi) while breathing normal room air (21% oxygen). patients then undergo another asl mri and cest-sage-epi while breathing medical grade air (100% oxygen). total asl mri and cest-sage-epi imaging scan time is 60 minutes.

Eligibility criteria:
inclusion criteria: * healthy volunteers will include persons who at the time of scans do not present with known neurological conditions that might impact tissue imaging results * patient participants should have suspected or pathology-confirmed diagnosis of a brain tumor (any histological subtype including brain metastases) * all participants must be able to obtain an mri scan and must be able to safely breathe high concentrations of oxygen exclusion criteria: * participants with contraindications to mri including metal implants * participants who are deemed not able to or not safe to breath high concentrations of oxygen
reiki breast surgery qol project for women undergoing breast surgery

Conditions: Breast Cancer

Summary: this pilot study will examine the impact of pre-operative medical reiki© on the psychosocial well-being and recovery of underserved women undergoing breast cancer surgery.

reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. practitioners lightly place their hands directly on or above the patient's body to transmit energy from the practitioner to the recipient. this process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself. reiki is a safe treatment modality that emphasizes spirituality in healing and wellness whose origins are rooted in ancient tibetan traditions. the prevalence of integrating complementary therapies such as reiki into mainstream medical practices is demonstrated by the number of hospitals that make use of these therapies to help alleviate, for example, the fatigue, pain, anxiety, and diminished quality of life experienced by cancer patients and those with other illnesses. reiki in particular, has become more widespread in cancer centers because of its potential to reduce cancer-related symptoms and enhanced wellness without posing harm to patients. a pilot double-blind randomized-controlled design will be used to engage 32 women in a pre-operative reiki intervention designed by raven keyes called medical reiki© with a follow-up of two months. women diagnosed with stage i-iii breast cancer undergoing mastectomy for their treatment will be recruited to study within two weeks of surgery. patients will be recruited to receive medical reiki© vs sham reiki (attention control) before surgery, with medical and psychosocial outcomes assessment conducted at three time points: -t0 - baseline/pre-surgery; t1 (1-month); t2 (2 months). these assessments will either be self-administered or administered via telephone by the research team. the study the study will aim to determine the feasibility of offering medical reiki to breast cancer patients immediately prior to breast surgery; the impact of pre-operative medical reiki© vs sham reiki on post-operative recovery at the identified timepoints based on the specified measures of subjective qol metrics and objective recovery metrics.

Eligibility criteria:
inclusion criteria: * ages 18-99 * breast cancer diagnosis stage 0-iii * undergoing unilateral or bilateral mastectomy (with or without reconstruction) within 2 weeks of recruitment * english speaking * from within 50 miles of bronx county, ny exclusion criteria: * current, uncontrolled psychiatric co-morbidities * pregnant women

Keywords: reiki
treatment of aids vacuolar myelopathy with methionine

Conditions: Myelopathy; AIDS-Myelopathy; AIDS Vacuolar Myelopathy

Summary: the purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

myelopathy is usually a late complication of aids, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. with prolonged survival and improved quality of life of hiv-infected patients, myelopathy is increasingly becoming a common source of disability. the cause of aids-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the hiv virus in the nervous system rather than the result of a direct infection. the purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

Eligibility criteria:
between 18 and 80 years of age

Keywords: myelopathy aids-myelopathy aids vacuolar myelopathy methionine
strokecopilot: a precision medicine tool in the stroke emergency

Conditions: Cerebrovascular Accident (CVA)

Summary: ischemic stroke or cerebral infarction (ci) is an immediate emergency affecting approximately 100,000 - 150,000 patients each year in france and is managed in the neurovascular intensive care unit (nicu). recanalization treatments can prevent disability, but patients must be carefully selected. knowledge in this field is evolving rapidly, which tends to make management more complex and personalized. in addition, the permanence of thrombolysis channels involves neurologists of all expertise. decision support tools are desirable to enable precision medicine in stroke. strokecopilot is a web application developed by the principal investigator. its algorithm contextualizes the patient in a set of evidence-based medicine references (recommendations and clinical trials) and gives the result of their cross-referencing to the user to indicate theoretical indications for intravenous thrombolysis and mechanical thrombectomy.


Eligibility criteria:
inclusion criteria: - adult patient (\>18 years old) admitted to the thrombolysis unit of the university hospital of strasbourg from january 01, 2017 to december 31, 2021 exclusion criteria: - subjects who have expressed their opposition to the use of their data for scientific research purposes.

Keywords: cerebrovascular accident (cva) ischemic stroke thrombolysis channels intravenous thrombolysis mechanical thrombectomy
effects of sildenafil on penile vascular function in hypertensive men with erectile dysfunction

Conditions: Arterial Hypertension; Erectile Dysfunction

Summary: the study will evaluate the effects of a chronic 30-day treatment with sildenafil citrate on penile and systemic microvascular function as well as in blood pressure. a control group of normotensive age-matched healthy subjects will serve as a comparator group for normal penile and systemic microvascular function.

vasculogenic erectile dysfunction (ed) is a highly prevalent health problem that is directly related with increased cardiovascular risk. in this context, phosphodiesterase type 5 inhibitors (pde5 inhibitors) are indicated in the treatment of ed because these drugs increase bioavailability of the endothelial-dependent potent vasodilator nitric oxide. thus, these drugs could also induce a reduction in arterial pressure and improve microvascular endothelial function in hypertensive patients. the primary aim of the study is to investigate the acute and chronic effects of sildenafil citrate (®viagra) on penile and systemic microvascular function of hypertensive patients presenting with ed. the secondary aim is to evaluate the effects of the treatment on arterial pressure. the study design is a prospective 2 x 2 cross-over, randomized, double blind clinical trial that will include 75 sexually active hypertensive men (age between 50-70 years) under anti-hypertensive treatment (arterial pressure \< 160/100 mmhg) presenting with ed. erectile function will be evaluated using the international index of erectile function (iief-5) questionnaire. patients with non-vasculogenic ed or diabetes will be excluded from the study. forty-five age-matched healthy subjects will be included as a comparator group. the evaluation of systemic microvascular function will be performed in the skin of the forearm and penile microvascular function in the skin of the base of the penis using the non-invasive methodology of laser speckle flowmetry coupled to cutaneous iontophoresis of a vasodilator (acetylcholine). in the acute protocol, microvascular evaluation will be carried out before and one hour after the oral administration of 100 mg of sildenafil citrate. in the chronic protocol, only hypertensive men will be randomized to receive either or placebo sildenafil 50 mg twice daily for 30 days. after a 30-day washout period the patients will receive the complementary treatment. the evaluation of penile and systemic microvascular function, as well as ambulatory blood pressure monitoring, will be performed before randomization and in the end of each treatment period.

Eligibility criteria:
inclusion criteria: * arterial hypertension stage i or ii * erectile dysfunction (vasculogenic) exclusion criteria: * diabetes * kidney, liver, neurologic and psychiatric diseases

Keywords: hypertension endothelial dysfunction erectile dysfunction sildenafil
optimization of hiv-1 dna genotyping by high throughput sequencing to document antiretroviral resistant mutations

Conditions: HIV-1-infection

Summary: the analysis of hiv resistance to antiretrovirals (sanger sequencing on rna) is difficult when the viral load is undetectable or during therapeutic breaks. in these situations, the ultra-deep sequencing (uds) can be done on proviral dna in order to improve characterization of archived resistant variants with may reflect past virological failures. this study is a cross-sectional study which will require only one additional tube which can be taken during a routine check-up as part of the usual follow-up of the individuals included.


Eligibility criteria:
inclusion criteria: * patient who has given consent * adult patient * patient living with hiv-1 * controlled viral load (\<50 rna copies/ml) for at least 1 year. * at least two previous virologic failures, either : * initial failure : defined as the persistence of a viral load greater than 50 copies/ml beyond 1 year, after the initiation of triple antiretroviral therapy, and without virological control (vl \> 50 copies/ml) since the initiation of the very first antiretroviral treatment. * a rebound in hiv viral load to more than 50 copies/ml after a period of virological success, confirmed on two consecutive samples at least one month apart. * at least 2 sanger rna genotypes have been done or could be done from the existing library. exclusion criteria: * patient not affiliated to a medical insurance scheme * protected adult * pregnant, parturient or breastfeeding woman * discontinuation of clinical and immuno-virological follow-up for more than 2 years
evaluation of the performance of chembio's dpp(r) syphilis screen & confirm rapid test system

Conditions: Syphilis

Summary: this study has been designed to evaluate the performance of the chembio diagnostics systems, inc. dpp® syphilis screen and confirm rapid test. the device is intended to qualitatively and simultaneously detect the presence of antibodies to non-treponemal and treponema pallidum antigens in whole blood (capillary and venous), serum or plasma.

syphilis is a sexually transmitted disease (std) caused by the spirochete treponema pallidum. it is a chronic bacterial infection that remains a public health concern worldwide, especially in resource poor settings. syphilis can be transmitted from infected women to their unborn children during pregnancy. worldwide 12 million individuals are diagnosed with syphilis each year, 90% of them in developing countries. diagnosed individuals are also at risk of becoming infected with and transmitting hiv \[1\]. early and appropriate diagnosis and treatment prevents the transmission and development of severe complications. a rapid serologic test for specific antibodies to non-treponemal and t. pallidum antigens is important in the early diagnosis and treatment monitoring of syphilis patients. in turn, this monitoring allows for the formulation of a more successful public health strategy. various serologic tests are currently available such as venereal disease research laboratory (vdrl), rapid plasma reagin (rpr), fluorescent treponemal antibody absorption (fta-abs) test, t. pallidum hemagglutination (tpha) test, immunoenzymatic assay (eia), treponema pallidum particle agglutination (tppa) test and western blot (wb) test \[2- 5\]. the chembio dpp syphilis screen \& confirm assay is a unique non-treponemal and treponemal rapid point-of-care test, which is simple and easy to use. the dpp syphilis screen \& confirm assay is a qualitative immunoassay for the detection of antibodies to the non-treponemal and t. pallidum antigens in serum, plasma and whole blood.

Eligibility criteria:
inclusion criteria: * must be at least 13 years of age (no upper age limit). * must be willing and able to receive post-test counseling, if applicable. * must sign (and be given) a copy of the written informed consent form and or assent form (if applicable). * must be able to sustain fingersticks and venipuncture from the arm or hand only. exclusion criteria: * persons who are under 13 years of age * persons who are unable to sustain venipuncture (as determined by investigator) * have previously participated in this clinical trial * persons who do not provide an informed consent, or withdraw consent.

Keywords: non-treponemal treponemal